{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:51:55Z","timestamp":1791157915428,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Int"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13340-026-00934-1","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:11:24Z","timestamp":1791155484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Arif","family":"Saleem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Shinwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfandyar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-5808","authenticated-orcid":false,"given":"Iftikhar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"1515797","DOI":"10.3389\/fpubh.2025.1515797","volume":"13","author":"X Huang","year":"2025","unstructured":"Huang X, Wu Y, Ni Y, Xu H, He Y. Global regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front Public Heal. 2025;13:1515797.","journal-title":"Front Public Heal"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"112152","DOI":"10.1016\/j.diabres.2025.112152","volume":"222","author":"A Ceriello","year":"2025","unstructured":"Ceriello A, Colagiuri SIDF. Global clinical practice recommendations for managing type 2 diabetes\u20132025. Diabetes Res Clin Pract. 2025;222:112152.","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 3","key":"934_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.15663","volume":"26","author":"CJ Bailey","year":"2024","unstructured":"Bailey CJ, Metformin. Therapeutic profile in the treatment of type 2 diabetes. Diabetes Obes Metab. 2024;26(Suppl 3):3\u201319.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"204201882098022","DOI":"10.1177\/2042018820980225","volume":"12","author":"C Baker","year":"2021","unstructured":"Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 2021;12:2042018820980225.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4239\/wjd.v14.i3.130","volume":"14","author":"PV Dludla","year":"2023","unstructured":"Dludla PV, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, Basson AK, Pheiffer C, Kengne AP. Pancreatic \u03b2-cell dysfunction in type 2 diabetes: implications of inflammation and oxidative stress. World J Diabetes. 2023;14:130\u201346.","journal-title":"World J Diabetes"},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ecl.2022.07.003","volume":"52","author":"S Hao","year":"2023","unstructured":"Hao S, Umpierrez GE, Daley T, Vellanki P. Intervention with therapeutic agents, understanding the path to remission in type 2 diabetes: part 1. Endocrinol Metab Clin North Am. 2023;52:27\u201338.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/dom.16206","volume":"27","author":"AYY Cheng","year":"2025","unstructured":"Cheng AYY, Heine RJ, Del Prato S, Green JB, Thieu VT, Zeytinoglu M. Striving for early effective glycaemic and weight management in type 2 diabetes: a narrative review. Diabetes Obes Metab. 2025;27:1708\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"e077097","DOI":"10.1136\/bmj-2023-077097","volume":"385","author":"P Bidulka","year":"2024","unstructured":"Bidulka P, Lugo-Palacios DG, Carroll O, O\u2019Neill S, Adler AI, Basu A, Silverwood RJ, Bartlett JW, Nitsch D, Charlton P, Briggs AH, Smeeth L, Douglas IJ, Khunti K, Grieve R. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data. BMJ. 2024;385:e077097.","journal-title":"BMJ"},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.2215\/CJN.10361016","volume":"11","author":"MK Yu","year":"2016","unstructured":"Yu MK, Kim SH. Second-line agents for the treatment of type 2 diabetes and prevention of CKD. Clin J Am Soc Nephrol. 2016;11:2104\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"E249","DOI":"10.1503\/cmaj.250591","volume":"198","author":"ES McNally","year":"2026","unstructured":"McNally ES, Marques P, Possik E, Pandya A, Tsoukas MA, Mavrakanas TA, Dasgupta K, Gupta N, Sharma A, Russell WA. Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada. Can Med Assoc J. 2026;198:E249\u201359.","journal-title":"Can Med Assoc J"},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"116464","DOI":"10.1016\/j.ejmech.2024.116464","volume":"272","author":"D-W Shao","year":"2024","unstructured":"Shao D-W, Zhao L-J, Sun J-F. Synthesis and clinical application of representative small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). Eur J Med Chem. 2024;272:116464.","journal-title":"Eur J Med Chem"},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.7326\/M23-2788","volume":"177","author":"A Qaseem","year":"2024","unstructured":"Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ, Balk EM, Cooney TG, Cross JTJ, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tufte JE, Etxeandia-Ikobaltzeta I, Yost J. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American college of physicians. Ann Intern Med. 2024;177:658\u201366.","journal-title":"Ann Intern Med"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"8145388","DOI":"10.1155\/2024\/8145388","volume":"2024","author":"S Chai","year":"2024","unstructured":"Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F. Comparison of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors as an add-on drug to insulin combined with oral hypoglycemic drugs: umbrella review. J Diabetes Res. 2024;2024:8145388.","journal-title":"J Diabetes Res"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1111\/dom.16550","volume":"27","author":"MJ Kim","year":"2025","unstructured":"Kim MJ, Cho YK, Kim S, Moon JY, Jung CH, Lee WJ. Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: an updated systematic review and meta-analysis with focus on an Asian subpopulation. Diabetes Obes Metab. 2025;27:5019\u201331.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR15","first-page":"e112","volume":"46","author":"MJ Page","year":"2022","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Panam Salud P\u00fablica. 2022;46:e112.","journal-title":"Rev Panam Salud P\u00fablica"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A, Population. Intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37:387.","journal-title":"Emerg Med J"},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:201.","journal-title":"Syst Rev"},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785\u201394.","journal-title":"Biometrics"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2288-14-109","volume":"14","author":"M Gjerdevik","year":"2014","unstructured":"Gjerdevik M, Heuch I. Improving the error rates of the begg and mazumdar test for publication bias in fixed effects meta-analysis. BMC Med Res Methodol. 2014;14:109.","journal-title":"BMC Med Res Methodol"},{"key":"934_CR20","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, Mcaleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials as an essential component of a. BMJ. 2019;326:l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1007\/s12325-023-02523-z","volume":"40","author":"RK Sahay","year":"2023","unstructured":"Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, Kumar SR, Sawardekar VM, Mishra A, Murthy LS, Arya VV, Sonawane AR, Soni PN, Gofne SK, Karnawat SR, Rajurkar MN, Patel PM, Lakhwani LK, Mehta SC, Joglekar SJ. Fixed-dose combination of dapagliflozin+ sitagliptin+ metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison with dual combinations. Adv Ther. 2023;40:3227\u201346.","journal-title":"Adv Ther"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/jod.jod_169_24","volume":"16","author":"P Kumthekar","year":"2025","unstructured":"Kumthekar P, Upadhyay MR, Tamma RR, Kranti V, Bhattacharya R, Sharma PK, Barge VB, Revankar S, Ghatge S. Fixed-dose combination of dapagliflozin and linagliptin in individuals with type 2 diabetes mellitus inadequately controlled on metformin: a randomized double-blind multicenter trial. J Diabetol. 2025;16:50\u20136.","journal-title":"J Diabetol"},{"key":"934_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13300-023-01504-3","volume":"15","author":"A Jain","year":"2024","unstructured":"Jain A, Vispute A, Dange A, Naskar A, Mondal A, Vivekanand B, Sharma B, Varade D, Shukla D, Bhatia G, Chaudhari H, Babu KR, Gavali O, Sorate S, Bhanushali S, Kothari V, Khandelwal V, Sharma A, Pawar R, Mayabhate M, Shahavi V, Rajput A, Jaiswal MA, Randomized. Double-blind, parallel-group phase III trial investigating the glycemic efficacy and safety profile of fixed-dose combination dapagliflozin and linagliptin over linagliptin monotherapy in patients with inadequately controlled type 2 diabetes. Diabetes Ther. 2024;15:215\u201327.","journal-title":"Diabetes Ther"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13410-024-01321-9","volume":"44","author":"AK Singh","year":"2024","unstructured":"Singh AK, Sahay R, Gil N, Tripathi S, Khandelwal V, Basu I, Shembalkar J, Srivastava MK, Bhatia G, Pathak V, Dange A, Chaudhri M, Naskar A, Mondal A, Gangwal P, Kumar S, Kumar D, Raju Ygnanasundara, Sorate S, Gavli O, Kumbalkar S, Varade D, Chaudhari H, Prasad D, Patil M, Bhagwat N, Agarwal R, Pandey A, Ghosh S, Patil S, Kini V, Sharma A, Mayabhate M, Pawar R, Rajput A, Shahavi VA. Randomized, double\u2013blind, active-controlled trial assessing the efficacy and safety of a fixed\u2013dose combination (FDC) of MEtformin hydrochloride 1000 Mg ER, SItagliptin phosphate 100 Mg, and DApagliflozin propanediol 10 Mg in Indian adults with type 2 D. Int J Diabetes Dev Ctries. 2024;44:67\u201376.","journal-title":"Int J Diabetes Dev Ctries"},{"key":"934_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12325-024-03037-y","volume":"42","author":"AK Singh","year":"2025","unstructured":"Singh AK, Das AK, Murthy LS, Ghosal S, Sahay R, Harikumar KVS, Keshava GH, Agarwal M, Vijayakumar G, Kalra P, Lodha P, Das S, Shaikh S, Goswami S, Ajish TP, Kumthekar P, Upadhyay M, Thamburaj A, Mahule A, Prasad A, Pednekar A. Efficacy of dapagliflozin+ sitagliptin+ metformin versus sitagliptin+ metformin in T2DM inadequately controlled on metformin monotherapy: a multicentric randomized trial. Adv Ther. 2025;42:801\u201312.","journal-title":"Adv Ther"},{"key":"934_CR27","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1111\/dom.15717","volume":"26","author":"KA Han","year":"2024","unstructured":"Han KA, Hwang Y-C, Moon SJ, Cho HC, Yoo HJ, Choi SH, Chon S, Kim K-A, Kim TN, Kang JG, Park C-Y, Won JC, Cho E, Kim J, Park KS. Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: the SOLUTION 2 study. Diabetes Obes Metab. 2024;26:3743\u201352.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/dom.13795","volume":"21","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perl S, Johnsson E, Garc\u00eda-s\u00e1nchez R, Jacob S. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21:2152\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P, Li Y, Cook W. Boaz Hirshberg; Iqbal, N. dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapaglif lozin addition versus single addition of saxagliptin or dapaglif lozin to metformin. Diabetes Care. 2015;38:376\u201383.","journal-title":"Diabetes Care"},{"key":"934_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Yanping D, Sheila Q, Bs S, Johnson J, Pharmd SGT, Lauring B, Mancuso JP, Engel SS. Brett Lauring. Ertugliflozin plus Sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20:1111\u201320.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/dom.13594","volume":"21","author":"Y Handelsman","year":"2019","unstructured":"Handelsman Y, Mathieu C, Prato SD, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21:883\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"934_CR32","doi-asserted-by":"crossref","unstructured":"DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015:1\u201310.","DOI":"10.2337\/dc14-2364"},{"key":"934_CR33","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1038\/s41598-018-22658-2","volume":"8","author":"SH Min","year":"2018","unstructured":"Min SH, Yoon J-H, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018;8:4466.","journal-title":"Sci Rep"},{"key":"934_CR34","doi-asserted-by":"crossref","unstructured":"Ma Y, Lin Y, Ding X, Peng Y. Comparing SGLT2i and other oral antidiabetic drugs as dual therapy add- \u00adon to metformin in type 2 diabetes: a systematic review and meta-analysis. Endocrinol Diabetes Metab, 2026, 9, e70176.","DOI":"10.1002\/edm2.70176"},{"key":"934_CR35","doi-asserted-by":"publisher","first-page":"e49050","DOI":"10.1097\/MD.0000000000049050","volume":"105","author":"AF Malik","year":"2026","unstructured":"Malik AF, Kashish F, Shivani F, Kumar S, Kumari V, Haseeb A, Mujtaba A, Raheem A, Ali SMS, Saleh U, Ahmad TKF. Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus. Med (Baltim). 2026;105:e49050.","journal-title":"Med (Baltim)"},{"key":"934_CR36","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.2337\/dc22-0784","volume":"45","author":"TODAY Study Group","year":"2022","unstructured":"TODAY Study Group. Long-term outcomes among young adults with type 2 diabetes based on durability of glycemic control: results from the TODAY cohort study. Diabetes Care. 2022;45:2689\u201397.","journal-title":"Diabetes Care"},{"key":"934_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12902-026-02286-y","volume":"26","author":"H Li","year":"2026","unstructured":"Li H, Fang Y, Zhang W. The role of resistance training in improving beta-cell function in type 2 diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2026;26:127.","journal-title":"BMC Endocr Disord"}],"container-title":["Diabetology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13340-026-00934-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13340-026-00934-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13340-026-00934-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:11:27Z","timestamp":1791155487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13340-026-00934-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s13340-026-00934-1","relation":{},"ISSN":["2190-1678","2190-1686"],"issn-type":[{"value":"2190-1678","type":"print"},{"value":"2190-1686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (as it is a systematic review using secondary data).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (as it is a systematic review using secondary data).","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"81"}}